Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Generics & Supergenerics Employing Defence & Growth Strategies: Brand Protection or Patent Busting |
 |
 |
 |
|
The change in the generics industry competitive landscape is driving the evolution of traditional business operating models. Companies are seeking further competitive advantage through innovation, differentiation and enhanced quality of products, striving for smarter, more profitable business models, cost effectiveness and faster routes to market. Traditional pharmaceutical innovators are coupling with generic manufacturers to better serve the healthcare sector with more companies like Novartis launching or acquiring generics arms to their businesses. With more than 30 drugs coming off-patent in the next 3-5 years, this will open up serious competition from the generics alternatives. Pharmaceutical innovators strive to protect their intellectual property and product brands by extending patents, whilst generic producers fight to occupy the new space in the market, capitalising on the new opportunities. As a result, the generics space is pitched for fundamental growth with revenues reaching more than $84bn by 2010. With this back-drop, SMi announces the 12th annual Generics & Super-generics conference. Holistic and controversial in its theme, the 2009 conference agenda aims to tackle the business and profitability issues and challenges faced by the generic manufacturers, but at the same time offering patent protection, intellectual property and patentability advice to the pharmaceutical innovators. Speakers are the generics players - presenting case studies & evaluating business models; key consultants, analysts and external experts - outlining policy, regulation and providing strategic tips around the challenges that this market faces. Topics that will be covered include: Intellectual Property protection: patentability, patent extensions and exclusivity |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis